What is Pacira BioSciences?
Non-opioid pain management and specialty pharmaceuticals company with $726.4M 2025 revenue; $177M Q1 2026 revenue scale.
- Category
- Non-opioid pain management and specialty pharmaceuticals
- Headquarters
- Tampa, FL
- Founded
- 2006
- Employees
- 900+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: PCRX
What is Pacira BioSciences?
Pacira BioSciences is a Non-opioid pain management and specialty pharmaceuticals company headquartered in Tampa, FL. As of June 2026, its clearest scale signal is $726.4M 2025 revenue; $177M Q1 2026 revenue.
Pacira BioSciences operates a specialty pharmaceutical company commercializing non-opioid pain products including EXPAREL, ZILRETTA, iovera, and related clinical programs. Its core customer set includes anesthesiologists, surgeons, hospitals, ambulatory surgery centers, orthopedic practices, payers, wholesalers, and patients, and its public product surface includes EXPAREL, ZILRETTA, iovera, DepoFoam technology, 5x30 strategy. The current scale signal is $726.4M 2025 revenue; $177M Q1 2026 revenue, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Pacira BioSciences offer?
Pacira BioSciences offers EXPAREL, ZILRETTA, iovera, DepoFoam technology and related healthcare workflows.
- EXPAREL· Core product
- ZILRETTA· Core product
- iovera· Core product
- DepoFoam technology· Workflow
- 5x30 strategy· Workflow
- Postsurgical pain programs· Workflow
- Osteoarthritis pain programs· Platform
- Training and provider education· Platform
How does Pacira BioSciences make money?
Pacira earns product revenue from branded pharmaceuticals and medical-device-enabled pain products sold through specialty distribution, wholesalers, hospitals, and provider channels.
Pacira earns product revenue from branded pharmaceuticals and medical-device-enabled pain products sold through specialty distribution, wholesalers, hospitals, and provider channels. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Pricing is product-, procedure-, contract-, payer-, and site-of-care specific; hospitals and ASCs evaluate net price after rebates, coverage, bundled-payment economics, and opioid-sparing value. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Pacira BioSciences?
Pacira BioSciences is led by Frank D. Lee, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Frank D. LeeChief Executive OfficerCEO since 2024Leads commercial execution and the 5x30 growth strategy.
- Kristen WilliamsChief Financial OfficerCFOOwns finance, reporting, and capital allocation.
- Max ReinhardtChief Legal and Administrative OfficerExecutive leaderLeads legal, compliance, and administrative functions.
- Roy WinstonChief Medical OfficerMedical leaderGuides clinical strategy and medical affairs.
How do you contact Pacira BioSciences's leadership?
Pacira BioSciences publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
Susan.Mesco@pacira.com (official published/company IR contact); personal executive format not verifiedHow much funding has Pacira BioSciences raised?
Pacira BioSciences is a public company (Nasdaq: PCRX), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2006: Founded - Pacira is formed around DepoFoam and non-opioid pain management assets. 2011: IPO - Pacira lists publicly on Nasdaq. 2018: Myoscience acquisition - Pacira adds iovera cold-therapy technology. 2021: Flexion acquisition - Pacira acquires ZILRETTA and broadens osteoarthritis pain exposure. 2026: Q1 2026 results - Pacira reports $177M of first-quarter revenue.
As of June 2026, Pacira BioSciences's practical funding capacity is best read through Nasdaq: PCRX, $726.4M 2025 revenue; $177M Q1 2026 revenue, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Pacira BioSciences access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Pacira BioSciences get here?
Pacira BioSciences grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2006Company foundedPacira focuses on non-opioid pain management.
- 2011Nasdaq listingPacira becomes a public company.
- 2018iovera addedThe Myoscience acquisition adds a device-enabled pain platform.
- 2021ZILRETTA addedFlexion brings an osteoarthritis pain product.
- 2025Record revenuePacira reports $726.4M of 2025 revenue.
- 2026Pipeline progressZILRETTA shoulder osteoarthritis study enrollment completes.
Who are Pacira BioSciences's competitors?
Pacira BioSciences competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- Heron TherapeuticsNon-opioid and supportive-care specialty pharma competitor.
- Collegium PharmaceuticalPain-management specialty pharmaceutical competitor.
- Avanos MedicalPain-management and surgical recovery technology competitor.
- MallinckrodtSpecialty pharmaceutical competitor in pain and hospital channels.
- PfizerLarge pharma competitor with analgesic and hospital-product reach.
- HikmaGeneric injectable and hospital-products competitor.
Pacira BioSciences — frequently asked questions
